daclizumab

Also found in: Wikipedia.

daclizumab

[dah-kliz´u-mab]

an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.

daclizumab

/da·cliz·u·mab/ (dah-kliz´u-mab) an immunosuppressant used to prevent acute organ rejection in renal transplant patients.

daclizumab

an immunosuppressant.

indications It is used to help prevent acute allograft rejection in renal transplant patients.

contraindications Known hypersensitivity to this drug contraindicates its use.

adverse effects Life-threatening effects are pulmonary edema, tachycardia, thrombosis, renal tubular necrosis, and hydronephrosis. Other adverse effects include headache, prickly sensation, coughing, atelectasis, congestion, constipation, abdominal pain, pyrosis, hypertension, bleeding, oliguria, dysuria, renal damage, and impaired wound healing. Common side effects include chills, tremors, dyspnea, wheezing, vomiting, nausea, and diarrhea.

daclizumab

Dacliximab, Zenapax^® Transplant medicine A monoclonal antibody used with other agents to ↓ transplant-related GVHD and organ rejection in kidney and liver graft recipients, and Pts with treatment refractory psoriasis, uveitis, tropical spastic paraparesis and some leukemias. See Kidney transplant.

daclizumab

A humanized monoclonal antibody against the interleukin-2 receptor. It is used to decrease the risk of organ rejection in kidney and heart transplants.

Mentioned in ?

References in periodicals archive ?

Mostly thymoglobulin, alemtuzumab, basiliximab, and daclizumab are used for this induction.

Advances in small bowel transplantation

Patients received either Thymoglobulin or daclizumab and showed a lower incidence of treatment failure as measured by the composite endpoint 12 months following transplantation.

Sanofi passes US FDA approval of Thymoglobulin for the prevention of acute kidney transplant rejection

Additionally, daclizumab (Zenapax), which was approved several years ago for prophylaxis of acute organ rejection in patients receiving renal transplants, was approved for multiple sclerosis treatment (Zinbryta) last year, and sofosbuvir (Sovaldi), which was approved in 2013 for the treatment of hepatitis C virus, is now combined with velpatasvir (Epclusa) to treat all six major forms of hepatitis C.

Novel drugs approved in 2016

En Colombia se cuenta con ATGAM, rATG y basiliximab, pero no con daclizumab y alemtuzumab.

Immunosuppressive drugs and major complications in pediatric renal transplantation/Inmunosupresores y principales complicaciones en el trasplante renal pediatrico/Imunossupressores e principais complicacoes no transplante renal pediatrico

33) Many other biologies have also been trialled in patients who have uveitis including: etanercept, adalimumab and daclizumab.

Non-infectious uveitis--current therapies and drugs in the pipeline

Zinbryta[TM], the brand name for daclizumab produced by Biogen and AbbVie, is an immune-modulating therapy taken by self-injection under the skin every four weeks.

People with relapsing forms of MS now have another option when other therapies haven't worked for them

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.

Construction and production of Foxp3-Fc (IgG) DNA vaccine/fusion protein

De ellos, cuatro tenian sindrome de VKH; uno era resistente al infliximab, uno resistente al daclizumab y los otros dos resistentes a los inmunosupresores convencionales.

Adalimumab como alternativa terapeutica en el sindrome de Vogt Koyanagi Harada refractario al infliximab: reporte de caso

These include tocilizumab, an inhibitor of proinflammatory cytokine interleukin (IL)-6; rituximab, an antiCD-20 monoclonal antibody; anakinra, an IL-1 antagonist; daclizumab, an IL-2 antagonist; and abatacept, a cytotoxic T lymphocyte-associated antigen 4 fusion protein that inhibits T cell co-stimulation.

Treatment of juvenile idiopathic arthritis-associated uveitis

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: Rejection and infection rates in 40 recipients during the early postoperative period.

Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model

All patients received induction with interleukin-2 receptor blocker daclizumab (100 mg/d) on the day of transplantation and 10 days after transplantation or basiliximab (40 mg at days 0 and 4), followed by triple therapy with prednisone, tacrolimus, or cyclosporine and mycophenolate mofetil.

Human polyomavirus 9 infection in kidney transplant patients

Monoclonal Infix Target Infix Source Suffix Antibody Name Transtuzumab Gemtuzumab tu-Tumor zu-humanized -mab Infliximab Basiliximab li-Immune system xi-chimeric Omalizumab Daclizumab li-Immune cells zu-humanised Palivizumab vi-viral zu-humanised Denosumab s-Bone cells u-human Rituximab tu-Tumor xi-chimeric Icrucumab c-cardiovascular u-human Guselkumab k-interleukin u-human Fosinumab n-nerve u-human Blintumomab tum-Tumor cells o-murine lymphocytes